

Spinal Muscular Atrophy (SMA) Highlights:

Updates from  **Biogen.**

Dear SMA Community,

As we embrace the arrival of spring, we celebrate the continued blossoming and strength of the SMA community.

We aspire to address the unmet needs of the SMA community and are grateful to individuals throughout the community for their willingness to share their family's lived experiences to enrich our collective and clinical understanding of SMA. We also honor the researchers who move the science forward as well as the patient advocates who work tirelessly to raise awareness and advocate for change.

We congratulate both SMA Europe and MDA for hosting successful conferences that offered the opportunity for inspired conversations about emerging scientific and clinical research. Thanks to your participation, we continue to make important progress in our understanding of how to combat this rare disease in different patient populations.

The latest updates from our SPINRAZA® (nusinersen) clinical development program can be found below.

– The Biogen Team

SMA Community Updates



Individual results may vary, e.g., with disease severity, initiation/duration of treatment.

We have continued our partnership with Tori and Morgan, lifelong friends and college students, as they navigate the challenges of early adulthood while living with SMA. Watch their story on People.com [here](#) to learn more about their journey.

Updates from Biogen

Biogen has added new resources to www.SPINRAZA.com around our SMA360° support program, additional educational tools and information, Spanish-language materials, and a video showing the experiences of three families whose children began treatment with SPINRAZA before the onset of SMA symptoms.

Highlights from 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

The 2024 MDA Clinical & Scientific Conference was held on March 3-6 and brought together leading researchers, clinicians, and industry professionals in neuromuscular diseases, including SMA. During the conference, we were pleased to make available the following updates:

- Biomarker data from the **RESPOND study in infants and toddlers treated with SPINRAZA who previously received gene therapy.**
 - Biogen continues to research biomarkers as potential indicators of neuron damage.
- These data from the RESPOND study were also presented at the 4th International Congress on Spinal Muscular Atrophy hosted by SMA Europe

Highlights from the 4th International Congress on Spinal Muscular Atrophy Hosted by SMA Europe

At the **4th International Congress on Spinal Muscular Atrophy hosted by SMA Europe**, we presented data from the SPINRAZA clinical development program and had the privilege of co-sponsoring and attending a **global SMA advocacy event** where patient advocacy groups from across the globe came together to engage with current issues affecting the SMA community and share learnings and strategies to help tackle these issues.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Click here to access full [Prescribing Information](#).

This information is not intended to replace discussions with your healthcare provider.